Human endogenous retrovirus K (HML-2) RNA and protein expression is a marker for human embryonic and induced pluripotent stem cells

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Fuchs, Nina V ^a,c   Loewer, Sabine ^b,c   Daley, George Q ^b   Izsvák, Zsuzsanna ^c   Löwer, Johannes ^a   Löwer, Roswitha ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Activation of human endogenous retrovirus K proviruses; Embryoid body differentiation; Human embryonic stem cells; Induced pluripotent stem cells; Pluripotency marker

Indexed keywords

ADAPTOR PROTEIN; BIOLOGICAL MARKER; GAG PROTEIN; MESSENGER RNA; REC PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS RNA;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; EMBRYONAL CARCINOMA STEM CELL; EMBRYONIC STEM CELL; GENE EXPRESSION; GENE LOCUS; GENE SILENCING; GROUP SPECIFIC ANTIGEN GENE; HUMAN; HUMAN CELL; HUMAN ENDOGENOUS RETROVIRUS K; LONG TERMINAL REPEAT; NONHUMAN; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; PROVIRUS; RETROVIRUS; SEQUENCE ANALYSIS; VIRUS EXPRESSION; VIRUS REACTIVATION;

HUMAN ENDOGENOUS RETROVIRUS K;

BIOLOGICAL MARKERS; BLOTTING, WESTERN; ENDOGENOUS RETROVIRUSES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL PROTEINS; VIRUS ACTIVATION;

EID: 84886024597     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-115     Document Type: Article

References (32)

1. Subramanian RP, Wildschutte JH, Russo C, Coffin JM. Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses. Retrovirology 2011, 8:90. 10.1186/1742-4690-8-90, 3228705, 22067224.
2. Fuchs NV, Kraft M, Tondera C, Hanschmann KM, Lower J, Lower R. Expression of the human endogenous retrovirus group HML-2/HERV-K does not depend on canonical promoter elements but is regulated by the transcription factors Sp1 and Sp3. J Virol 2011, 85:3436-3448. 10.1128/JVI.02539-10, 3067833, 21248046.
3. Magin C, Lower R, Lower J. cORF and RcRE, the Rev/Rex and RRE/RxRE homologues of the human endogenous retrovirus family HTDV/HERV-K. J Virol 1999, 73:9496-9507. 112984, 10516058.
4. Armbruester V, Sauter M, Krautkraemer E, Meese E, Kleiman A, Best B, et al. A novel gene from the human endogenous retrovirus K expressed in transformed cells. Clin Cancer Res 2002, 8:1800-1807.
5. Kaufmann S, Sauter M, Schmitt M, Baumert B, Best B, Boese A, et al. Human endogenous retrovirus protein Rec interacts with the testicular zinc-finger protein and androgen receptor. J Gen Virol 2010, 91:1494-1502. 10.1099/vir.0.014241-0, 20147518.
6. Denne M, Sauter M, Armbruester V, Licht JD, Roemer K, Mueller-Lantzsch N. Physical and functional interactions of human endogenous retrovirus proteins Np9 and rec with the promyelocytic leukemia zinc finger protein. J Virol 2007, 81:5607-5616. 10.1128/JVI.02771-06, 1900259, 17360752.
7. Boese A, Sauter M, Galli U, Best B, Herbst H, Mayer J, et al. Human endogenous retrovirus protein cORF supports cell transformation and associates with the promyelocytic leukemia zinc finger protein. Oncogene 2000, 19:4328-4336. 10.1038/sj.onc.1203794, 10980608.
8. Armbruester V, Sauter M, Roemer K, Best B, Hahn S, Nty A, et al. Np9 protein of human endogenous retrovirus K interacts with ligand of numb protein X. J Virol 2004, 78:10310-10319. 10.1128/JVI.78.19.10310-10319.2004, 516385, 15367597.
9. Hanke K, Chudak C, Kurth R, Bannert N. The Rec protein of HERV-K(HML-2) upregulates androgen receptor activity by binding to the human small glutamine-rich tetratricopeptide repeat protein (hSGT). Int J Cancer 2013, 132:556-567. 10.1002/ijc.27693, 22733359.
10. Flockerzi A, Ruggieri A, Frank O, Sauter M, Maldener E, Kopper B, et al. Expression patterns of transcribed human endogenous retrovirus HERV-K(HML-2) loci in human tissues and the need for a HERV Transcriptome Project. BMC Genomics 2008, 9:354. 10.1186/1471-2164-9-354, 2525661, 18664271.
11. Seifarth W, Frank O, Zeilfelder U, Spiess B, Greenwood AD, Hehlmann R, et al. Comprehensive analysis of human endogenous retrovirus transcriptional activity in human tissues with a retrovirus-specific microarray. J Virol 2005, 79:341-352. 10.1128/JVI.79.1.341-352.2005, 538696, 15596828.
12. Kleiman A, Senyuta N, Tryakin A, Sauter M, Karseladze A, Tjulandin S, et al. HERV-K(HML-2) GAG/ENV antibodies as indicator for therapy effect in patients with germ cell tumors. Int J Cancer 2004, 110:459-461. 10.1002/ijc.11649, 15095315.
13. Wang-Johanning F, Liu J, Rycaj K, Huang M, Tsai K, Rosen DG, et al. Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int J Cancer 2007, 120:81-90. 10.1002/ijc.22256, 17013901.
14. Humer J, Waltenberger A, Grassauer A, Kurz M, Valencak J, Rapberger R, et al. Identification of a melanoma marker derived from melanoma-associated endogenous retroviruses. Cancer Res 2006, 66:1658-1663. 10.1158/0008-5472.CAN-05-2452, 16452225.
15. Hahn S, Ugurel S, Hanschmann KM, Strobel H, Tondera C, Schadendorf D, et al. Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability. AIDS Res Hum Retroviruses 2008, 24:717-723. 10.1089/aid.2007.0286, 18462078.
16. Wang-Johanning F, Rycaj K, Plummer JB, Li M, Yin B, Frerich K, et al. Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. J Natl Cancer Inst 2012, 104:189-210. 10.1093/jnci/djr540, 3274512, 22247020.
17. Lower R. The pathogenic potential of endogenous retroviruses: facts and fantasies. Trends Microbiol 1999, 7:350-356. 10.1016/S0966-842X(99)01565-6, 10470042.
18. Lower R, Boller K, Hasenmaier B, Korbmacher C, Muller-Lantzsch N, Lower J, et al. Identification of human endogenous retroviruses with complex mRNA expression and particle formation. Proc Natl Acad Sci U S A 1993, 90:4480-4484. 10.1073/pnas.90.10.4480, 46535, 8506289.
19. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451:141-146. 10.1038/nature06534, 18157115.
20. Loewer S, Cabili MN, Guttman M, Loh YH, Thomas K, Park IH, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet 2010, 42:1113-1117. 10.1038/ng.710, 3040650, 21057500.
21. Jaenisch R, Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 2008, 132:567-582. 10.1016/j.cell.2008.01.015, 18295576.
22. Armstrong L, Hughes O, Yung S, Hyslop L, Stewart R, Wappler I, et al. The role of PI3K/AKT, MAPK/ERK and NFkappabeta signalling in the maintenance of human embryonic stem cell pluripotency and viability highlighted by transcriptional profiling and functional analysis. Hum Mol Genet 2006, 15:1894-1913. 10.1093/hmg/ddl112, 16644866.
23. Chen G, Gulbranson DR, Yu P, Hou Z, Thomson JA. Thermal stability of fibroblast growth factor protein is a determinant factor in regulating self-renewal, differentiation, and reprogramming in human pluripotent stem cells. Stem Cells 2012, 30:623-630. 10.1002/stem.1021, 3538808, 22213113.
24. Bock C, Kiskinis E, Verstappen G, Gu H, Boulting G, Smith ZD, et al. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 2011, 144:439-452. 10.1016/j.cell.2010.12.032, 3063454, 21295703.
25. Santoni FA, Guerra J, Luban J. HERV-H RNA is abundant in human embryonic stem cells and a precise marker for pluripotency. Retrovirology 2012, 9:111. 10.1186/1742-4690-9-111, 3558390, 23253934.
26. Wissing S, Munoz-Lopez M, Macia A, Yang Z, Montano M, Collins W, et al. Reprogramming somatic cells into iPS cells activates LINE-1 retroelement mobility. Hum Mol Genet 2012, 21:208-218. 10.1093/hmg/ddr455, 3235014, 21989055.
27. Ruprecht K, Ferreira H, Flockerzi A, Wahl S, Sauter M, Mayer J, et al. Human endogenous retrovirus family HERV-K(HML-2) RNA transcripts are selectively packaged into retroviral particles produced by the human germ cell tumor line Tera-1 and originate mainly from a provirus on chromosome 22q11.21. J Virol 2008, 82:10008-10016. 10.1128/JVI.01016-08, 2566279, 18684837.
28. Schmitt K, Reichrath J, Roesch A, Meese E, Mayer J. Transcriptional Profiling of Human Endogenous Retrovirus Group HERV-K(HML-2) Loci in Melanoma. Genome Biol Evol 2013, 5:307-328. 10.1093/gbe/evt010, 3590776, 23338945.
29. Paces J, Huang YT, Paces V, Ridl J, Chang CM. New insight into transcription of human endogenous retroviral elements. N Biotechnol 2013, 30:314-318. 10.1016/j.nbt.2012.11.009, 23201072.
30. Vinuelas J, Kaneko G, Coulon A, Vallin E, Morin V, Mejia-Pous C, et al. Quantifying the contribution of chromatin dynamics to stochastic gene expression reveals long, locus-dependent periods between transcriptional bursts. BMC Biol 2013, 11:15. 10.1186/1741-7007-11-15, 3635915, 23442824.
31. Galli UM, Sauter M, Lecher B, Maurer S, Herbst H, Roemer K, et al. Human endogenous retrovirus rec interferes with germ cell development in mice and may cause carcinoma in situ, the predecessor lesion of germ cell tumors. Oncogene 2005, 24:3223-3228. 10.1038/sj.onc.1208543, 15735668.
32. Singh AM, Dalton S. The cell cycle and Myc intersect with mechanisms that regulate pluripotency and reprogramming. Cell Stem Cell 2009, 5:141-149. 10.1016/j.stem.2009.07.003, 2909475, 19664987.